Non-Hodgkin Lymphoma Therapeutics Market Size & Share, by Type of Therapy (Chemotherapy, Radiation Therapy, Target Therap); Cell Type (B-Cell Lymphoma, T-Cell Lymphoma); Distribution Channel (Retail Pharmacies & Drug Stores, Hospital Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5584
  • Published Date: Jan 29, 2024
  • Report Format: PDF, PPT

Top Featured Companies Dominating the Non-Hodgkin Lymphoma Therapeutics Market

top-features-companies
    • AbbVie, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer Inc.
    • GSK plc.  
    • Novartis AG
    • Bayer AG
    • Bausch Health Companies Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • November 15, 2023: The FDA approved SIRPant-M's investigational new drug (IND) application in May 2023 after reviewing preclinical data that indicated the medication was effective against a range of solid tumours as well as hematologic tumours.
  • May 19, 2023: AbbVie announced that EPKINLYTM (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) that have undergone two or more lines of systemic therapy and are relapsed or refractory (R/R).

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5584
  • Published Date: Jan 29, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are surge in geriatric population, rise in environmental exposure, and growth in approval of medications.

The market size of Non-Hodgkin lymphoma therapeutics is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market AbbVie, Inc., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc. are and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying